The presentation will include results from the company’s multicenter investigational device exemption (IDE) pilot study of a second-generation system that delivers SSO2 therapy for reduction of infarct size after an AMI.
SSO2 therapy is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart muscle in heart attack patients.
TherOx president and CEO Kevin T Larkin said: "We’re very pleased with the early data and its relevance toward our goal of providing substantially better options for treating heart attack patients."
The TherOx system creates SSO2 therapy by mixing highly oxygenated saline with the patient’s blood and delivers it through a catheter directly to the targeted ischemic area of the heart.
The first generation system to deliver SSO2 therapy received the CE Mark and was successful in meeting the safety and effectiveness endpoints in the AMIHOT II trial.
Statistical results from the AMIHOT II trial of SSO2 therapy, together with PCI and stenting, demonstrated a relative reduction of 26% in infarct size compared to PCI and stenting alone.
